Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)

Published:2022 Issue:4 Volume:157 Page:254-260
ISSN:0015-5691
Container-title:Folia Pharmacologica Japonica
language:en
Short-container-title:Folia Pharmacol. Jpn.

Author:

Yamada Yoshihisa¹,Fujiki Hiroyuki¹,Mizuguchi Hiroshi¹,Takeshita Yukinobu¹,Hattori Katsuji¹,Ohmoto Koji²,Aihara Miki³,Nagano Keisuke⁴,Isakari Yoshimasa⁵,Yamamoto Miho⁶,Yamamura Yoshitaka⁷

Affiliation:

1. Department of Renal and Cardiovascular Research, Otsuka Pharmaceutical Co., Ltd.

2. Department of Medical Innovation, Otsuka Pharmaceutical Co., Ltd.

3. Medical Affairs, Otsuka Pharmaceutical Co., Ltd.

4. Scientific Partnering, Otsuka Pharmaceutical Co., Ltd.

5. Pharmaceutical Planning Department, Otsuka Pharmaceutical Co., Ltd.

6. Regulatory Affairs Department, Otsuka Pharmaceutical Co., Ltd.

7. Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd.

Publisher

Japanese Pharmacological Society

Subject

Pharmacology

Link

https://www.jstage.jst.go.jp/article/fpj/157/4/157_22006/_pdf

Reference43 articles.

1. 1) 新田孝作, 他. 透析会誌. 2020;53:579-632.

2. 2) 成田一衛, 他. エビデンスに基づく多発性嚢胞腎PKD診療ガイドライン2020. 東京医学社.

3. 3) The European Polycystic Kidney Disease Consortium. Cell. 1994;77:881-894.

4. 4) Mochizuki T, et al. Science. 1996;272:1339-1342.

5. 5) Bergmann C, et al. Nat Rev Dis Primers. 2018;4:1-24.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP